問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Nephrology

更新時間:2023-09-19

高治圻Kao, Chih-Chin
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -3 個月

篩選

List

33Cases

2024-09-30 - 2028-11-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2024-12-01 - 2030-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-06-01 - 2027-12-31

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-07-01 - 2030-12-31

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
23Sites

Recruiting23Sites

2026-06-01 - 2031-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    錠劑 膜衣錠

Participate Sites
14Sites

Recruiting14Sites

2025-10-15 - 2028-10-31

Phase II

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-12-01 - 2027-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting1Sites

2026-08-15 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
  • Condition/Disease

    Renal Insufficiency, Chronic

  • Test Drug

    膠囊劑 錠劑

Participate Sites
16Sites

Not yet recruiting16Sites

2026-05-31 - 2030-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2023-12-28 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4